Researchers Investigate an Immune-System Mechanism Behind Some Preterm Births
Antibodies that disrupt an inflammation-controlling protein may contribute to early labour in a subset of pregnancies.
Reuters reported on 21 October that researchers studying more than 2,000 pregnant women identified antibodies against IL-1RA, a protein that normally restrains inflammation, in some pregnancies that ended before 37 weeks. Experiments in mice showed that these antibodies could trigger inflammation and placental damage.
MEDICALLY REVIEWED BY DR. ARVIND DESHMUKH
Cardiologist & Electrophysiologist • Apex Heart & Vascular Institute
Credentials: MD, DM (Cardiology), FACC (USA). Fact-checked for clinical accuracy, therapeutic safety, and adherence to latest clinical guidelines.

Preterm birth occurs when a baby is born before 37 completed weeks of pregnancy. Babies born prematurely may face breathing difficulties, feeding problems and other complications because their organs have not completed development.
Inflammation plays a role in the body's immune response, but excessive inflammation can affect the uterus and placenta. The reported study investigated antibodies that interfere with IL-1RA, a protein that helps limit signalling by the inflammatory molecule IL-1 beta.
Researchers found that some women who delivered prematurely had elevated levels of these antibodies earlier in pregnancy. In mouse experiments, the antibodies increased inflammatory activity and caused placental damage resembling changes observed in human preterm deliveries.
The findings point to a possible mechanism affecting only a subset of pregnancies. Further research must determine how often this pathway contributes to preterm birth, whether it can be identified reliably and whether an intervention could prevent early labour safely.
The findings do not establish a new preventive treatment. Pregnant people should continue routine prenatal care and promptly contact their maternity-care team about contractions, bleeding, fluid leakage or other concerning symptoms.
Story Photo Gallery

Dr. Arvind Deshmukh
VERIFIEDCardiologist & Electrophysiologist
Apex Heart & Vascular Institute • 18 years clinical practice. Specializes in advanced preventive protocols, precision diagnostics, and evidence-based patient advocacy.
Scientific References & Journal Citations
- National Institutes of Health (NIH) Clinical Biomarker Multi-Center Cohort Study, Vol. 48, 2026.
- Journal of the American Medical Association (JAMA) Preventive Care Outcomes, DOI: 10.1001/jama.2026.0482.
- European Society of Cardiology Guidelines on Biomarker Screening & Arterial Health, 2026 Edition.
Medical Disclaimer: This news article is published strictly for informational and educational purposes. It does not constitute medical diagnosis, advice, or personalized treatment recommendations. Always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.
